These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15755858)

  • 1. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
    Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
    Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
    J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.
    Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B
    J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
    van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
    Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.
    Nikolaou A; Thomas D; Kampanellou C; Alexandraki K; Andersson LG; Sundin A; Kaltsas G
    J Endocrinol Invest; 2010 Dec; 33(11):794-9. PubMed ID: 20332708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PET in localization of neuroendocrine and adrenocortical tumors.
    Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B
    Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors.
    Carlbom L; Caballero-Corbalán J; Granberg D; Sörensen J; Eriksson B; Ahlström H
    Ups J Med Sci; 2017 Mar; 122(1):43-50. PubMed ID: 27894208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
    Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
    J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential value of EUS in pancreatic surveillance of VHL patients.
    van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Koopmans KP; Kema IP; Zonnenberg BA; Timmers HJ; de Herder WW; Sluiter WJ; de Vries EG; Links TP
    Eur J Endocrinol; 2016 May; 174(5):611-20. PubMed ID: 26884551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
    Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
    Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11C-5-hydroxytryptophan positron emission tomography after radiofrequency ablation of neuroendocrine tumor liver metastases.
    Norlén O; Nilsson A; Krause J; Stålberg P; Hellman P; Sundin A
    Nucl Med Biol; 2012 Aug; 39(6):883-90. PubMed ID: 22381780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
    Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
    Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
    Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
    Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other PET tracers for neuroendocrine tumors.
    Koopmans KP; Glaudemans AW
    PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.
    Leboulleux S; Dromain C; Vataire AL; Malka D; Aupérin A; Lumbroso J; Duvillard P; Elias D; Hartl DM; De Baere T; Guigay J; Schlumberger M; Ducreux M; Baudin E
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3021-8. PubMed ID: 18522978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.
    Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
    Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
    Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.